Health & TechHouston, Texas
A new lung cancer pill helped patients live longer in a Phase 3 trial
In the 338-patient Krascendo 1 trial, divarasib cut the risk of death by 44 percent versus currently approved KRAS G12C drugs. Median survival was 17.7 months, compared with 12.0, with fewer severe side effects.
Verified · MD Anderson Cancer Center